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PROCEDURE FOR PREPARING OF LIVER HISTOLOGY SLIDES 
Overview:  Histology  involves  the  use  of  a  set  of  techniques  to  examine  the 
morphology, architecture and composition of tissues. The liver tissue samples was 
first dissected and fixed. Then the liver tissue samples was embedded in paraffin 
wax. After the tissue has been sliced, sections were mounted on a slide and then 
the  sections  were  stained  in  preparation  for  examination  by  light  microscope 
(Olympus BX61) to identification of hepatic steatosis, hepatic inflammation and 
Mallory bodies via Hematoxylin Eosin staining. There were eight stages in the 
preparation of liver histology slides  as following: 
Fixation:  it is performed to preserve the biological structures (both chemically 
and structurally) of the liver tissues in as natural a state as possible and prevent  
autolysis and putrefaction. This requires a chemical fixative that can stabilise the 
proteins, nucleic acids and mucosubstances of the liver tissues by making them 
insoluble. This process provides rigidity to the liver tissue, making it easier to 
section. 
 
 
  
 
The  liver  tissues  samples  were  fixed  in  a  Common  chemical  fixative, 
which  was  10%  formaldehyde  (10%formalin).  The  liver  tissue  samples  are 
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immersed in the amount of formaldehyde equivalent to 15-20 times of the sample 
size and the duration of fixation was less than 48 hours. Once fixation has been 
completed, the  liver tissue samples was embedded prior to sectioning. 
Dehydrated: liver Tissue samples  processing was done to remove water from the 
liver tissues, replacing such water with a medium that solidifies, setting very hard 
and so allowing extremely  thin sections to be sliced. 
  
  
   
 
 
 
 
 
 
This process was done by using graded ethanol solutions  as follows (70%, 
80%,  95%,  95%,  100%,  100%,  100%)  respectively,  leaving  the  liver  tissue 
samples  in  each  solution  for  a  sufficient  period  for  replaced  the  water  with 
alcohol. And despite the fact that paraffin is not soluble in alcohol, therefor the 
alcohol replaces with the  paraffin solvent has capable to soluble with paraffin.   
Clearing:  Xylene  solution  used,  usually,  to  clean  the tissue  mass    by  passing 
through graded xylene solutions, that ultimately lead to replacement of alcohol 
with xylene and then the liver tissue mass were becoming ready-to-Embed. 
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Embedding: Before sectioning, liver tissue samples were embedded in paraffin 
wax. After a short time in the liquid paraffin, the  liver tissue samples placed into 
a mold with more paraffin. The wax was allowed to solidify, forming a block that 
can be held in a microtome. This step was allowed the liver tissues to be cut easily 
by a microtome. 
 
 
 
 
 
Sectioning:  Liver  tissue  samples  embedded  in  paraffin  were  mounted  in  the 
microtome. The method used to actually cut sections from the hardened block of 
tissue depends on the type of microscopy that will be used to observe it and hence 
the thickness of sample required. The liver tissue samples will be examined by  
using light microscopy, thereby  liver tissue sections were cut at 5 µm with rotary 
microtome. After sectioning, the slices were  placed on a slide. 
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Mounting:  After  several  slices  of  the  paraffin-embedded  tissue  have  been 
sectioned, the slices are removed from the blade and floated atop a warm water 
bath to smooth out the sample.  
 
After the slides were dried, they are placed in an oven to "bake" the paraffin. The 
oven is warm and helps the section of tissue adhere to the slide.    
 
 
 
 
 
Mountin
g 
Drying slides 
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Staining: Finally, the mounted sections are treated with an appropriate histology 
stain. One especially common stain is Hematoxylin and Eosin (H&E), colors the 
nuclei dark blue (hematoxylin) and the remaining cell components pink (eosin). 
For  staining,  slides  are  put  into  a  staining  rack  and  then  manually  processed 
through  the  staining  row.  After  finishing,  slides  are  dried  in  incubator  before 
mounting the cover slip. For "blueing", running fresh tap water is needed.  The 
staining is performed in this order:- 
Heat  slides  in  incubator  for  15min  to  liquify  paraffin,and  then  the  slides  was 
immersed in Xylene, alcohol 100%, alcohol 100%, alcohol 95%, alcohol 95%, 
alcohol  70%,  alcohol  50%,  Stains:  Hematoxylin  Eosin  staining,  alcohol  70%, 
alcohol 95%, alcohol 95%, alcohol 100%, alcohol 100%, xylene and ultimately 
the slides was dried in oven and then mount cover slip respectively. 
 
 
 
 
 
 
 
Above; (1) rehydration row to remove paraffin and make tissue susceptible for 
dye. (2) dehydration to cover with rasin and glass slip.  
 
 
H&E 
Rehydration row to remove paraffin and make tissue susceptible 
        Dehydration to cover with rasin and glass slip 
5 min  2 min  2 min  5 min  8 min  2 min 
5 min 
5 min  5 min 
5 min  5 min 
5 min  5 min 
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APPENDIX 3 
HEPATIC TISSUE CHANGES SCORING, GRADING  
AND ITS EXAMINATION RESULTS BY TWO PATHOLOGISTS 
 
Hepatic tissue changes scoring and grading system 
Histological diagnosis of hepatic 
steatosis by NASH activity score 
Histological diagnosis of hepatic inflammation by  
Knodell scoring system 
The degree of 
liver steatosis 
% Range of 
liver steatosis 
score  The degree of 
Porta inflammation   
Score  The degree of 
Mallory bodies 
None  <5%  0  Non porta inflammation               0  Present 
Mild  5-33%  1  Mild(sprinkling of 
inflammatory cells in < 1/3 
of portal tracts) .                          
1  Non present 
Moderate  33-66%  2  Moderate (increase  
inflammatory cells in 1/3-2/3 
of portal tracts).                           
3   
Severe  >66%  3  Marked (dense packingof 
inflammatory  cells in >2/3 
of portal tracts) .           
4   
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Groups  First pathologist result  Second pathologist result 
Treatment of 
groups 
The degree 
of liver 
steatosis 
The degree  
of  Portal 
inflammation 
The presence 
of Mallory 
bodies 
The degree  
of liver 
steatosis 
The degree  
of  Portal 
inflammation 
The presence  
of Mallory 
bodies 
Control group  Sever  Marked  None present  Moderate  Marked  Present 
Control group  Sever  Moderate  Present  Severe  Moderate  Present 
Control group  Moderate  Marked  Present  Moderate  Marked  Present 
Control group  Sever  Marked  None present  Severe  Marked  Present 
Control group  Sever  Marked  Present  Severe  Marked  Present 
Control group  Sever  Moderate  Present  Severe  Marked  Present 
Group 1  Moderate  Moderate  None present  Severe  Moderate  Present 
Group 1  Sever  Moderate  None present  Moderate  Mild  None present 
Group 1  Sever  Moderate  Present  Severe  Moderate  Present 
Group 1  Moderate  Moderate  None present  Moderate  Moderate  Present 
Group 1  Moderate  Moderate  Present  Moderate  Moderate  Present 
Group 1  Sever  Marked  None present  Severe  Moderate  Present 
Group 2  Mild  Moderate  None present  Mild  Mild  Present 
Group 2  Mild  Moderate  Present  Mild  Moderate  Present 
Group 2  Moderate  Mild  None present  Moderate  Mild  None present 
Group 2  Mild  Mild  None present  Mild  Mild  None present 
Group 2  Moderate  Moderate  None present  Moderate  Mild  None present 
Group 2  Moderate  Mild  None present  Moderate  Mild  None present 
Group 3  Mild  Mild  None present  Mild  None  None present 
Group 3  Mild  Mild  None present  None  Mild  None present 
Group 3  Mild  Mild  None present  Mild  Mild  None present 
Group 3  None  None  None present  None  None  None present 
Group 3  Mild  Mild  None present  Mild  Mild  None present 
Group 3  Mild  None  None present  Mild  None  None present 
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Groups  First pathologist result 
 
Second pathologist result 
 
Treatment of 
groups 
The degree 
of liver 
steatosis 
The degree 
of  Portal 
inflammation 
The presence  
of Mallory 
bodies 
The degree 
of liver 
steatosis 
The degree 
of  Portal 
inflammation 
The presence  
of Mallory 
bodies 
Control group  3  4  1  2  4  0 
Control group  3  3  0  3  3  0 
Control group  2  4  0  2  4  0 
Control group  3  4  1  3  4  0 
Control group  3  4  0  3  4  0 
Control group  3  4  0  3  3  0 
Group 1  2  3  1  3  3  0 
Group 1  3  1  1  2  3  1 
Group 1  3  3  0  3  3  0 
Group 1  2  3  1  2  3  0 
Group 1  2  3  0  2  3  0 
Group 1  3  3  1  3  4  0 
Group 2  1  1  1  1  3  0 
Group 2  1  3  0  1  3  0 
Group 2  2  1  1  2  1  1 
Group 2  1  1  1  1  1  1 
Group 2  2  1  1  2  3  1 
Group 2  2  1  1  2  1  1 
Group 3  1  0  1  1  1  1 
Group 3  1  1  1  0  1  1 
Group 3  1  1  1  1  1  1 
Group 3  0  0  1  0  0  1 
Group 3  1  1  1  1  1  1 
Group 3  1  0  1  1  0  1 
 
 
 
 
 
 
 
Results Of Hepatic Tissue Changes Examination By Two Pathologists  85 
 
APPENDIX 4 
THE INTER-PATHOLOGISTS AGREEMENT 
 
The inter-pathologists agreement for diagnosis of hepatic steatosis . 
 
Crosstabs 
Case Processing Summary 
  Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Diagnosis by pathologest 1 * 
Diagnosis by pathologist 2 
24  51.1%  23  48.9%  47  100.0% 
 
Diagnosis by pathologest 1 * Diagnosis by pathologist 2 Crosstabulation 
      Diagnosis by pathologist 2 
Total        None  Mild  Moderate  Severe 
Diagnosis by pathologest 1  None  Count  1  0  0  0  1 
Expected Count  .1  .3  .3  .3  1.0 
Mild  Count  1  7  0  0  8 
Expected Count  .7  2.3  2.7  2.3  8.0 
Moderate  Count  0  0  6  1  7 
Expected Count  .6  2.0  2.3  2.0  7.0 
Sever  Count  0  0  2  6  8 
Expected Count  .7  2.3  2.7  2.3  8.0 
Total  Count  2  7  8  7  24 
Expected Count  2.0  7.0  8.0  7.0  24.0 
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The inter-pathologists agreement for diagnosis of hepatic inflammation .   
 
Crosstabs 
Case Processing Summary 
  Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Diagnosis by pathologest 1 * 
Diagnosis by pathologist 2 
24  51.1%  23  48.9%  47  100.0% 
Diagnosis by pathologest 1 * Diagnosis by pathologist 2 Crosstabulation 
      Diagnosis by pathologist 2 
Total        None  Mild  Moderate  Marked 
Diagnosis by pathologest 1 
None 
Count  2  1  0  0  3 
Expected Count  .3  .9  1.3  .6  3.0 
Mild 
Count  0  6  3  0  9 
Expected Count  .8  2.6  3.8  1.9  9.0 
Moderate 
Count  0  0  6  1  7 
Expected Count  .6  2.0  2.9  1.5  7.0 
Marked 
Count  0  0  1  4  5 
Expected Count  .4  1.5  2.1  1.0  5.0 
Total 
Count  2  7  10  5  24 
Expected Count  2.0  7.0  10.0  5.0  24.0 
Symmetric Measures 
    Value  Asymp. Std. Error
a  Approx. T
b  Approx. Sig. 
Measure of Agreement  Kappa  .764  .107  5.903  .000 
N of Valid Cases  24       
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null hypothesis. 87 
 
 
The inter-pathologists agreement for diagnosis of Mallory bodies. 
Crosstabs 
Case Processing Summary 
  Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Diagnosis by pathologest 1 * 
Diagnosis by pathologist 2 
24  51.1%  23  48.9%  47  100.0% 
Diagnosis by pathologest 1 * Diagnosis by pathologist 2 Crosstabulation 
      Diagnosis by pathologist 2 
Total        Present  None present 
Diagnosis by pathologest 1  Present  Count  6  1  7 
Expected Count  2.0  5.0  7.0 
None present  Count  1  16  17 
Expected Count  5.0  12.0  17.0 
Total  Count  7  17  24 
Expected Count  7.0  17.0  24.0 
 
 
 
Symmetric Measures 
    Value  Asymp. Std. Error
a  Approx. T
b  Approx. Sig. 
Measure of Agreement  Kappa  .650  .124  5.278  .000 
N of Valid Cases  24       
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null hypothesis. 
Symmetric Measures 
    Value  Asymp. Std. Error
a  Approx. T
b  Approx. Sig. 
Measure of Agreement  Kappa  .798  .136  3.911  .000 
N of Valid Cases  24       
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null hypothesis. 88 
 
APPENDIX 5 
 
Distribution of  hepatic steatosis data and hepatic inflammation data  in 
percents between control group and treatment groups  
 
Explore 
Treatment groups 
Case Processing Summary 
 
Treatment groups 
Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Hepatic steatosis  Control group  6  100.0%  0  .0%  6  100.0% 
Group 1  6  100.0%  0  .0%  6  100.0% 
Group 2  6  100.0%  0  .0%  6  100.0% 
Group 3  6  100.0%  0  .0%  6  100.0% 
Descriptives 
  Treatment groups  Statistic  Std. Error 
Hepatic steatosis  Control group  Mean  2.83  .167 
95% Confidence 
Interval for Mean 
Lower Bound  2.40   
Upper Bound  3.26   
5% Trimmed Mean  2.87   
Median  3.00   
Variance  .167   
Std. Deviation  .408   
Minimum  2   
Maximum  3   
Range  1   
Interquartile Range  0   
Skewness  -2.449-  .845 
Kurtosis  6.000  1.741 89 
 
Group 1  Mean  2.50  .224 
95% Confidence 
Interval fo 
r Mean 
Lower Bound  1.93   
Upper Bound  3.07   
5% Trimmed Mean  2.50   
Median  2.50   
Variance  .300   
Std. Deviation  .548   
Minimum  2   
Maximum  3   
Range  1   
Interquartile Range  1   
Skewness  .000  .845 
Kurtosis  -3.333-  1.741 
Group 2  Mean  1.50  .224 
95% Confidence 
Interval for Mean 
Lower Bound  .93   
Upper Bound  2.07   
5% Trimmed Mean  1.50   
Median  1.50   
Variance  .300   
Std. Deviation  .548   
Minimum  1   
Maximum  2   
Range  1   
Interquartile Range  1   
Skewness  .000  .845 
Kurtosis  -3.333-  1.741 
Group 3  Mean  .83  .167 
95% Confidence 
Interval for Mean 
Lower Bound  .40   
Upper Bound  1.26   
5% Trimmed Mean  .87   90 
 
Median  1.00   
Variance  .167   
Std. Deviation  .408   
Minimum  0   
Maximum  1   
Range  1   
Interquartile Range  0   
Skewness  -2.449-  .845 
Kurtosis  6.000  1.741 
Tests of Normality 
 
Treatment groups 
Kolmogorov-Smirnov
a  Shapiro-Wilk 
  Statistic  Df  Sig.  Statistic  df  Sig. 
Hepatic steatosis  Control group  .492  6  .000  .496  6  .000 
Group 1  .319  6  .056  .683  6  .004 
Group 2  .319  6  .056  .683  6  .004 
Group 3  .492  6  .000  .496  6  .000 
a. Lilliefors Significance Correction 
 
Detrended Normal Q-Q Plot of Hepatic steatosis 
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Explore 
 
Treatment groups 
Case Processing Summary 
 
Treatment groups 
Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Hepatic inflammation  Control group  6  100.0%  0  .0%  6  100.0% 
Group 1  6  100.0%  0  .0%  6  100.0% 
Group 2  6  100.0%  0  .0%  6  100.0% 
Group 3  6  100.0%  0  .0%  6  100.0% 
Descriptives 
 
Treatment groups  Statistic 
Std. 
Error 
Hepatic inflammation  Control group  Mean  3.83  .167 
95% Confidence Interval 
for Mean 
Lower Bound  3.40   
Upper Bound  4.26   
5% Trimmed Mean  3.87   
Median  4.00   
Variance  .167   
Std. Deviation  .408   
Minimum  3   
Maximum  4   
Range  1   
Interquartile Range  0   
Skewness  -2.449-  .845 
Kurtosis  6.000  1.741 
Group 1  Mean  2.67  .333 
95% Confidence Interval 
for Mean 
Lower Bound  1.81   
Upper Bound  3.52   
5% Trimmed Mean  2.74   92 
 
Median  3.00   
Variance  .667   
Std. Deviation  .816   
Minimum  1   
Maximum  3   
Range  2   
Interquartile Range  0   
Skewness  -2.449-  .845 
Kurtosis  6.000  1.741 
Group 2  Mean  1.33  .333 
95% Confidence Interval for 
Mean 
Lower 
Bound 
.48   
Upper 
Bound 
2.19   
5% Trimmed Mean  1.26   
Median  1.00   
Variance  .667   
Std. Deviation  .816   
Minimum  1   
Maximum  3   
Range  2   
Interquartile Range  0   
Skewness  2.449  .845 
Kurtosis  6.000  1.741 
Group 3  Mean  .50  .224 
95% Confidence Interval for 
Mean 
Lower 
Bound 
-.07-   
Upper 
Bound 
1.07   
5% Trimmed Mean  .50   
Median  .50   93 
 
Variance  .300   
Std. Deviation  .548   
Minimum  0   
Maximum  1   
Range  1   
Interquartile Range  1   
Skewness  .000  .845 
Kurtosis  -3.333-  1.741 
Tests of Normality 
 
Treatment groups 
Kolmogorov-Smirnov
a  Shapiro-Wilk 
  Statistic  Df  Sig.  Statistic  df  Sig. 
Hepatic inflammation  Control group  .492  6  .000  .496  6  .000 
Group 1  .492  6  .000  .496  6  .000 
Group 2  .492  6  .000  .496  6  .000 
Group 3  .319  6  .056  .683  6  .004 
a. Lilliefors Significance Correction 
 
Detrended Normal Q-Q Plot of Hepatic inflammation 
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Explore 
Case Processing Summary 
 
Treatment groups 
Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Mallory bodies  Control group  6  100.0%  0  .0%  6  100.0% 
Group 1  6  100.0%  0  .0%  6  100.0% 
Group 2  6  100.0%  0  .0%  6  100.0% 
Group 3  6  100.0%  0  .0%  6  100.0% 
Descriptives
a 
 
Treatment groups  Statistic 
Std. 
Error 
Mallory bodies  Control 
group 
Mean  .33  .211 
95% Confidence Interval for Mean  Lower Bound  -.21-   
Upper Bound  .88   
5% Trimmed Mean  .31   
Median  .00   
Variance  .267   
Std. Deviation  .516   
Minimum  0   
Maximum  1   
Range  1   
Interquartile Range  1   
Skewness  .968  .845 
Kurtosis  -1.875-  1.741 
Group 1  Mean  .67  .211 
95% Confidence Interval for Mean  Lower Bound  .12   
Upper Bound  1.21   
5% Trimmed Mean  .69   
Median  1.00   
Variance  .267   95 
 
Std. Deviation  .516   
Minimum  0   
Maximum  1   
Range  1   
Interquartile Range  1   
Skewness  -.968-  .845 
Kurtosis  -1.875-  1.741 
Group 2  Mean  .83  .167 
95% Confidence Interval for Mean  Lower Bound  .40   
Upper Bound  1.26   
5% Trimmed Mean  .87   
Median  1.00   
Variance  .167   
Std. Deviation  .408   
Minimum  0   
Maximum  1   
Range  1   
Interquartile Range  0   
Skewness  -2.449-  .845 
Kurtosis  6.000  1.741 
a. Mallory bodies is constant when Treatment groups = Group 3. It has been omitted. 
 
Tests of Normality
b 
 
Treatment groups 
Kolmogorov-Smirnov
a  Shapiro-Wilk 
  Statistic  Df  Sig.  Statistic  Df  Sig. 
Mallory bodies  Control group  .407  6  .002  .640  6  .001 
Group 1  .407  6  .002  .640  6  .001 
Group 2  .492  6  .000  .496  6  .000 
a. Lilliefors Significance Correction 
b. Mallory bodies is constant when Treatment groups = Group 3. It has been omitted. 
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Detrended Normal Q-Q Plots of Mallory bodies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Explore 
Case Processing Summary 
  Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Hepatic steatosis  24  100.0%  0  .0%  24  100.0% 
Hepatic inflammation  24  100.0%  0  .0%  24  100.0% 
Mallory bodies  24  100.0%  0  .0%  24  100.0% 
Descriptives 
      Statistic  Std. Error 
Hepatic steatosis  Mean  1.92  .190 
95% Confidence Interval for 
Mean 
Lower Bound  1.52   
Upper Bound  2.31   
5% Trimmed Mean  1.95   
Median  2.00   
Variance  .862   
Std. Deviation  .929   97 
 
Minimum  0   
Maximum  3   
Range  3   
Interquartile Range  2   
Skewness  -.179-  .472 
Kurtosis  -1.145-  .918 
Hepatic inflammation  Mean  2.38  .275 
95% Confidence Interval for 
Mean 
Lower Bound  1.81   
Upper Bound  2.94   
5% Trimmed Mean  2.42   
Median  3.00   
Variance  1.810   
Std. Deviation  1.345   
Minimum  0   
Maximum  4   
Range  4   
Interquartile Range  2   
Skewness  -.411-  .472 
Kurtosis  -1.279-  .918 
Mallory bodies  Mean  .71  .095 
95% Confidence Interval for 
Mean 
Lower Bound  .51   
Upper Bound  .90   
5% Trimmed Mean  .73   
Median  1.00   
Variance  .216   
Std. Deviation  .464   
Minimum  0   
Maximum  1   
Range  1   
Interquartile Range  1   
Skewness  -.979-  .472 98 
 
Case Processing Summary 
  Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Hepatic steatosis  24  100.0%  0  .0%  24  100.0% 
Hepatic inflammation  24  100.0%  0  .0%  24  100.0% 
Kurtosis  -1.145-  .918 
Tests of Normality 
  Kolmogorov-Smirnov
a  Shapiro-Wilk 
  Statistic  Df  Sig.  Statistic  df  Sig. 
Hepatic steatosis  .213  24  .006  .846  24  .002 
Hepatic inflammation  .304  24  .000  .835  24  .001 
Mallory bodies  .443  24  .000  .573  24  .000 
a. Lilliefors Significance Correction 
 
 
Hepatic steatosis 
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Hepatic inflammation 
 
 
 
 
Mallory bodies 
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NPar Tests 
Kruskal-Wallis Test 
Ranks 
  Treatment groups  N  Mean Rank 
Hepatic steatosis  Control group  6  19.25 
Group 1  6  16.75 
Group 2  6  9.25 
Group 3  6  4.75 
Total  24   
Hepatic inflammation  Control group  6  21.00 
Group 1  6  14.67 
Group 2  6  9.33 
Group 3  6  5.00 
Total  24   
 
 
 
 
 
 
 
 
 
 
 
NPar Tests 
Mann-Whitney Test 
Ranks 
  Treatment groups  N  Mean Rank  Sum of Ranks 
Hepatic steatosis  Control group  6  7.50  45.00 
Group 1  6  5.50  33.00 
Total  12     
Hepatic inflammation  Control group  6  9.08  54.50 
Group 1  6  3.92  23.50 
Total  12     
Test Statistics
a,b 
  Hepatic steatosis  Hepatic inflammation 
Chi-Square  17.848  18.823 
df  3  3 
Asymp. Sig.  .000  .000 
a. Kruskal Wallis Test 
b. Grouping Variable: Treatment groups 101 
 
Test Statistics
b 
  Hepatic steatosis  Hepatic inflammation 
Mann-Whitney U  12.000  2.500 
Wilcoxon W  33.000  23.500 
Z  -1.173-  -2.762- 
Asymp. Sig. (2-tailed)  .241  .006 
Exact Sig. [2*(1-tailed Sig.)]  .394
a  .009
a 
a. Not corrected for ties. 
b. Grouping Variable: Treatment groups 
 
NPar Tests 
Mann-Whitney Test 
Ranks 
  Treatment groups  N  Mean Rank  Sum of Ranks 
Hepatic steatosis  Control group  6  9.25  55.50 
Group 2  6  3.75  22.50 
Total  12     
Hepatic inflammation  Control group  6  9.42  56.50 
Group 2  6  3.58  21.50 
Total  12     
 
 
 
 
 
Test Statistics
b 
  Hepatic steatosis  Hepatic inflammation 
Mann-Whitney U  1.500  .500 
Wilcoxon W  22.500  21.500 
Z  -2.815-  -3.028- 
Asymp. Sig. (2-tailed)  .005  .002 
Exact Sig. [2*(1-tailed Sig.)]  .004
a  .002
a 
a. Not corrected for ties. 
b. Grouping Variable: Treatment groups 102 
 
NPar Tests 
Mann-Whitney Test 
Ranks 
  Treatment groups  N  Mean Rank  Sum of Ranks 
Hepatic steatosis  Control group  6  9.50  57.00 
Group 3  6  3.50  21.00 
Total  12     
Hepatic inflammation  Control group  6  9.50  57.00 
Group 3  6  3.50  21.00 
Total  12     
Test Statistics
b 
  Hepatic steatosis  Hepatic inflammation 
Mann-Whitney U  .000  .000 
Wilcoxon W  21.000  21.000 
Z  -3.108-  -3.035- 
Asymp. Sig. (2-tailed)  .002  .002 
Exact Sig. [2*(1-tailed Sig.)]  .002
a  .002
a 
a. Not corrected for ties. 
b. Grouping Variable: Treatment groups 
 
NPar Tests 
Mann-Whitney Test 
Ranks 
  Treatment groups  N  Mean Rank  Sum of Ranks 
Hepatic steatosis  Group 1  6  8.75  52.50 
Group 2  6  4.25  25.50 
Total  12     
Hepatic inflammation  Group 1  6  8.50  51.00 
Group 2  6  4.50  27.00 
Total  12     
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Test Statistics
b 
  Hepatic steatosis  Hepatic inflammation 
Mann-Whitney U  4.500  6.000 
Wilcoxon W  25.500  27.000 
Z  -2.345-  -2.211- 
Asymp. Sig. (2-tailed)  .019  .027 
Exact Sig. [2*(1-tailed Sig.)]  .026
a  .065
a 
a. Not corrected for ties. 
b. Grouping Variable: Treatment groups 
 
NPar Tests 
Mann-Whitney Test 
Ranks 
  Treatment groups  N  Mean Rank  Sum of Ranks 
Hepatic steatosis  Group 1  6  9.50  57.00 
Group 3  6  3.50  21.00 
Total  12     
Hepatic inflammation  Group 1  6  9.25  55.50 
Group 3  6  3.75  22.50 
Total  12     
Test Statistics
b 
  Hepatic steatosis  Hepatic inflammation 
Mann-Whitney U  .000  1.500 
Wilcoxon W  21.000  22.500 
Z  -3.035-  -2.815- 
Asymp. Sig. (2-tailed)  .002  .005 
Exact Sig. [2*(1-tailed Sig.)]  .002
a  .004
a 
a. Not corrected for ties. 
b. Grouping Variable: Treatment groups 
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NPar Tests 
Mann-Whitney Test 
Ranks 
 
Treatment groups  N  Mean Rank  Sum of Ranks 
Hepatic steatosis  Group 2  6  8.25  49.50 
Group 3  6  4.75  28.50 
Total  12     
Hepatic inflammation  Group 2  6  8.25  49.50 
Group 3  6  4.75  28.50 
Total  12     
Test Statistics
b 
  Hepatic steatosis  Hepatic inflammation 
Mann-Whitney U  7.500  7.500 
Wilcoxon W  28.500  28.500 
Z  -2.021-  -2.021- 
Asymp. Sig. (2-tailed)  .043  .043 
Exact Sig. [2*(1-tailed Sig.)]  .093
a  .093
a 
a. Not corrected for ties. 
b. Grouping Variable: Treatment groups 
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APPENDIX 6 
ASSOCIATION  BETWEEN  ADMINISTRATION OF NIGELLA SATIVA 
SEEDS AND  MALLORY BODIES 
 
The Kendall's tau-b test  
Crosstabs 
Case Processing Summary 
  Cases 
  Valid  Missing  Total 
  N  Percent  N  Percent  N  Percent 
Treatment groups * Mallory bodies  24  100.0%  0  .0%  24  100.0% 
Treatment groups * Mallory bodies Crosstabulation 
      Mallory bodies 
Total        Present  None present 
Treatment groups  Control group  Count  4  2  6 
Expected Count  1.8  4.3  6.0 
Group 1  Count  2  4  6 
Expected Count  1.8  4.3  6.0 
Group 2  Count  1  5  6 
Expected Count  1.8  4.3  6.0 
Group 3  Count  0  6  6 
Expected Count  1.8  4.3  6.0 
Total  Count  7  17  24 
Expected Count  7.0  17.0  24.0 
Symmetric Measures 
    Value  Asymp. Std. Error
a  Approx. T
b  Approx. Sig. 
Ordinal by Ordinal  Kendall's tau-b  .487  .127  3.250  .001 
N of Valid Cases  24       
a. Not assuming the null hypothesis. 
b. Using the asymptotic standard error assuming the null hypothesis. 106 
 
 APENDIX 7 
RESEARCH PICTURES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Three doses of Nigella sativa seeds 
extract ( 0.5,1,1.5 g/kg/day for 8weeks) 
Dose of ethanol ( 4ml of 40% 
ethanol/day for 8 weeks ) 
 Wistar rats housed in metal cages 
   Ethanol 
40% 107 
 
 
Administration of rats with Nigella sativa seeds extract along with ethanol by 
using the intragastric feeding model (sonde tube). 
 
 
 
 
Taking the liver tissue after termination 
 Gross liver tissue 108 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     Examination of liver tissue slides by first pathologist 
 
 
 
 
                  
 
 
 
Examination of liver tissue slides with first pathologist in Pathology Anatomy 
Department of Diponegoro University Semarang 
Liver tissue slides  Liver tissue block                         109 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A,  B,  C  ; Representative  liver sections  from  Wistar rats with ethanol  induced 
hepatic steatosis,  inflammation, Mallory  bodies present on control group  with 
Haematoxylin Eosin (H&E) staining examination by using (A, 20× B, 20× and C, 
40×). D, E, F ; Representative liver sections from Wistar rats  pretreated with 
Nigella sativa seeds extract on treatment group3 with Haematoxylin Eosin (H&E) 
staining examination by using (D, 20× E, 20× and F, 40×). 
 
A 
B 
C 
E 
D 
F 110 
 
 
 
 
 
 
 
Haematoxylin  Eosin  (H&E)  staining  examination  by  using  400X 
magnification. Liver section in the control group, shows  hepatocytes with severe 
hepatic steatosis as form small fat droplets (thin arrow), large fat droplets (thick 
arrow), marked inflammatory cells infiltrated as form lymphocytic( arrowhead), 
Mallory bodies is present ( tailed arrow). 
 
  
 
 
 
 
 
 
Haematoxylin  Eosin  (H&E)  staining  examination  by  using  400X 
magnification. Liver section in group 1, shows most of field with severe hepatic 
steatosis  (long  thin  arrow,  thick  arrow)  and  moderate  hepatic  inflammation 
(arrowhead), some of  hepatocytes contain Mallory bodies (tailed arrow). 111 
 
 
 
 
 
 
 
 
Haematoxylin  Eosin  (H&E)  staining  examination  by  using  400X 
magnification. Liver section in group2, shows a hepatocyte with moderate most 
hepatic steatosis as form small fat droplets (long thin arrow), mild inflammatory 
cells infiltrated as form lymphocytic(arrowhead). Inflammation is usually mixed 
but  it  can  predominantly  be  either  neutrophilic  or  lymphocytic.Mallory  bodies 
none present. 
 
 
 
 
 
 
 
Haematoxylin  Eosin  (H&E)  staining  examination  by  using  400X 
magnification.  Liver section  in group 3, shows  hepatocyte with  mild hepatic 
steatosis (long thin arrow). Most of the fields showed mild inflammatory cells 
infiltrated (arrowhead). Mallory bodies none present in hepatocytes. 